Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful ActivityValsamo Anagnostou, Patrick M. Forde, Franco Verde et al.|Clinical Cancer Research|2017Cited by 181
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinomaDaniel Shu, Mark Yarchoan|Nature Immunology|2024Cited by 84
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D’Alessio, David J. Pinato, Bernardo Stefanini et al.|The Lancet Oncology|2024Cited by 64
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinomaDaniel J. Zabransky, Mark Yarchoan|Hepatology|2024Cited by 9